Pharmaceutical Technology's In the Lab eNewsletter, July 2023

When evaluating a drug’s risk assessment for elemental impurities, one must consider all aspects of its lifecycle.

When evaluating a drug’s risk assessment for elemental impurities, one must consider all aspects of its lifecycle.

The companies hope address the need for efficient collection, cryopreservation, quality control, and logistics capabilities of leukapheresis materials to support various aspects of the cell therapy workflow.

The Segmentation by Exogenous Perfusion system uses a cell’s location in the tumor to find differences in gene activity.

Sandbox AQ’s molecular simulation division is collaborating with companies like AstraZeneca and Sanofi to develop novel treatments for various disorders.

Researchers at the University of Waterloo have developed a liquid-liquid encapsulation system for use in sustainable encapsulation processes.

Eli Lilly & Company will pay Verve Therapeutics up to $525 million to advance a lipoprotein gene editing research program.

The bioreactor scaler tool helps scaling between development and manufacturing and to de-risk scaling activities and ensure product quality.

The integration of the binders into a routine lateral flow test will support the clinical and commercial development of rapid diagnostics for Alzheimer’s disease through nasal sampling.

Charles River’s off-the-shelf lentiviral vector packaging plasmids are intended for use with cell and gene therapies.

Sartorius and Waters will collaborate to develop integrated analytical solutions for downstream biomanufacturing.